1. Academic Validation
  2. Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats

Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats

  • Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6758-63. doi: 10.1073/pnas.0308292101.
Jorge D Brioni 1 Robert B Moreland Marlon Cowart Gin C Hsieh Andrew O Stewart Petter Hedlund Diana L Donnelly-Roberts Masaki Nakane James J Lynch 3rd Teodozyi Kolasa James S Polakowski Mark A Osinski Kennan Marsh Karl-Erik Andersson James P Sullivan
Affiliations

Affiliation

  • 1 Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA. jorge.brioni@abbott.com
Abstract

Apomorphine, a nonselective Dopamine Receptor Agonist, facilitates penile erection and is effective in patients suffering from erectile dysfunction. The specific Dopamine Receptor subtype(s) responsible for its erectogenic effect is not known. Here we report that the dopamine D(4) receptor plays a role in the regulation of penile function. ABT-724 is a selective dopamine D(4) receptor agonist that activates human dopamine D(4) receptors with an EC(50) of 12.4 nM and 61% efficacy, with no effect on dopamine D(1), D(2), D(3), or D(5) receptors. ABT-724 dose-dependently facilitates penile erection when given s.c. to conscious rats, an effect that is blocked by haloperidol and clozapine but not by domperidone. A proerectile effect is observed after intracerebroventricular but not intrathecal administration, suggesting a supraspinal site of action. s.c. injections of ABT-724 increase intracavernosal pressure in awake freely moving rats. In the presence of sildenafil, a potentiation of the proerectile effect of ABT-724 is observed in conscious rats. The ability of ABT-724 to facilitate penile erection together with the favorable side-effect profile indicates that ABT-724 could be useful for the treatment of erectile dysfunction.

Figures
Products